Mali pioneers hybrid malaria vaccine approach to protect children

The Republic of Mali has taken a groundbreaking step in the global fight against malaria by becoming the first nation to implement a hybrid vaccination approach, strategically aligning vaccine doses with seasonal transmission patterns. This innovative method, launched on World Malaria Day, positions Mali as the 20th African country to incorporate malaria vaccines into routine immunization programs, marking a significant milestone in public health.

why this hybrid approach matters for malaria control in Mali

Malaria transmission in Mali follows a distinct seasonal pattern, with the highest burden occurring between July and December. The hybrid vaccination strategy addresses this challenge by administering the first three doses throughout the year based on age, followed by seasonal booster doses in May or June—just before the peak transmission period. This timing ensures that children aged five to 36 months receive maximum protection when they need it most.

Mali recorded 8.15 million malaria cases in 2023, representing 3.1% of global cases, and 14,328 deaths, accounting for 2.4% of worldwide fatalities. The country ranks among the 11 nations bearing the heaviest malaria burden globally, with an estimated 1.4 million additional cases reported between 2019 and 2023—highlighting the urgent need for innovative interventions like this hybrid vaccination model.

vaccine deployment targets high-risk regions

The R21/Matrix-M malaria vaccine will be rolled out in 19 priority districts across five regions: Kayes, Koulikoro, Mopti, Ségou, and Sikasso. With an initial supply of 927,800 doses, the program aims to reach vulnerable populations most affected by seasonal surges in transmission.

key benefits of the hybrid vaccination strategy

• Enhanced protection during peak transmission: Seasonal vaccine administration aligns peak immunity with the highest risk periods, maximizing effectiveness.
• Scalable and adaptable: The approach can be tailored to other regions with similar seasonal malaria patterns, offering a template for future public health strategies.
• Evidence-backed results: Clinical trials in Mali demonstrate that seasonal dosing can reduce malaria cases by up to 75% in high-transmission zones, where child mortality rates are disproportionately high.

collaborative efforts behind Mali’s malaria vaccine initiative

The Ministry of Health and Social Development of Mali, in partnership with Gavi, the United Nations Children’s Fund (UNICEF), and the World Health Organization (WHO), spearheaded this initiative. The project received funding and technical support from these organizations to ensure seamless integration into the country’s Expanded Programme on Immunization (EPI).

Colonel Assa Badiallo Touré, Mali’s Minister of Health, emphasized the collaborative nature of the effort: “This milestone reflects the dedication of researchers, health workers, and global partners whose work has made this life-saving vaccine a reality. While challenges remain, we are committed to scaling this approach to protect every child at risk.”

global perspectives on malaria vaccination

Gavi, which leads the global malaria vaccination program, has delivered over 24 million doses across 20 African countries. Dr. Sania Nishtar, Gavi’s CEO, underscored the urgency of sustained funding: “Every child deserves access to this critical tool. With malaria claiming hundreds of thousands of lives annually in Africa, continued investment is non-negotiable.”

UNICEF’s Representative in Mali, Dr. Pierre Ngom, added: “After decades of research, this vaccine provides a powerful new weapon against malaria. However, it must complement existing measures like insecticide-treated nets and seasonal chemoprevention to achieve lasting impact.”

The WHO also played a pivotal role in validating the vaccine’s safety and efficacy through pilot programs in Ghana, Kenya, and Malawi. These trials, which involved over two million children, demonstrated a 13% reduction in child mortality and supported the WHO’s recommendation for widespread use of the RTS,S/AS01 and R21/Matrix-M vaccines.

broader implications for Africa’s malaria fight

Since 2023, malaria vaccine rollouts have accelerated across the continent, with countries like Uganda and Cameroon expanding their programs. By the end of 2025, an estimated 13 million additional children in Africa are expected to be protected by these vaccines. Looking ahead, Gavi aims to scale up efforts to safeguard 50 million children by 2030, pending sufficient funding.

As the first country to adopt a hybrid vaccination strategy, Mali sets a precedent for other nations grappling with seasonal malaria surges. This innovative approach not only enhances child survival but also reinforces Africa’s collective resilience against one of the continent’s deadliest diseases.

frequently asked questions about malaria vaccination in Mali

who should receive the malaria vaccine in Mali?

Children aged five to 36 months are the primary targets, as they face the highest risk of severe illness and death from malaria.

how does the hybrid vaccination approach work?

The first three doses are administered year-round based on age, while the fourth and fifth doses are given seasonally—typically in May or June—before the peak transmission period.

are the vaccines safe and effective?

Yes. The R21/Matrix-M and RTS,S/AS01 vaccines are WHO-prequalified and have demonstrated over 50% efficacy in reducing malaria cases during the first year of vaccination. Seasonal dosing has shown even greater impact in high-risk areas.

what other malaria prevention methods are used in Mali?

In addition to vaccination, the country employs insecticide-treated nets, seasonal malaria chemoprevention, intermittent preventive treatment during pregnancy, and indoor residual spraying to combat the disease.